Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
31 results about "HGF Receptor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Inhibitors of VEGF receptor and HGF receptor signaling
ActiveUS20070004675A1Promote motilityPromote invasionBiocideOrganic chemistryVEGF receptorsHGF Receptor
The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions
Owner:MIRATI THERAPEUTICS INC
Inhibitors of protein tyrosine kinase activity
This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling and HGF receptor signaling. More particularly, the invention relates to compounds, compositions and methods for the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
Owner:METHYLGENE
Five-membered heterocycle pyrimidine compounds, preparation method and application thereof
The invention relates to five-membered heterocycle pyrimidine compounds, their pharmaceutical acceptable salt or pharmaceutical acceptable solvate and a preparation method thereof. The five-membered heterocycle pyrimidine compounds possess a c-Met inhibitory activity and have a structure as shown in the general formula 1. The invention also relates to a drug combination which contains the compounds and applications of the compounds in preparation of drugs used for prevention and treatment of in vivo Hepatocyte Growth Factor Receptor (HGFR) related abnormal cell proliferation, morphologic change and hyperkinesis associated diseases, angiogenesis or cancer metastasis associated diseases, and especially for prevention and treatment of tumor growth and metastasis.
Owner:SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Inhibitors of VEGF receptor and hgf receptor signaling
ActiveUS20060287343A1Invasive growth is enhancedPromote invasionBiocideOrganic chemistryCompound (substance)VEGF receptors
The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions
Owner:METHYLGENE
Inhibitors of VEGF receptor and HGF receptor signaling
ActiveUS20060074056A1Promote motilityPromote invasionBiocideOrganic chemistryVEGF receptorsHGF Receptor
The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions
Owner:METHYLGENE
Pyridine chemical, its preparation method, and pharmaceutical composition containing the chemical and application thereof
The invention relates to a pyridine chemical shown as the following general formula and having c-Met and / or ALK inhibitory activity and its pharmaceutically-acceptable salt or pharmaceutically-acceptable solvate, a preparation method thereof, a pharmaceutical composition containing the chemicals, and applications of the chemicals in preparation of medicines for preventing and treating abnormal proliferation and morphological change of cells and related diseases, such as hyperkiesis, related to hepatocyte growth factor receptor (HGFR) and / or anaplastic lymphoma kinase (ALK) in organism and diseases related to vascularization or cancerometastasis, especially application in preparation of medicines for treating and preventing growth and metastasis of tumor.
Owner:CHIA TAI TIANQING PHARMA GRP CO LTD
Five-membered heterocycle pyrimidine compounds, preparation method and application thereof
Owner:SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Inhibitors of protein tyrosine kinase activity
ActiveUS20090264440A1Promote motilityPromote invasionBiocideSenses disorderKinase activityProtein-Tyrosine Kinases
This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling and HGF receptor signaling. More particularly, the invention relates to compounds, compositions and methods for the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
Owner:MIRATI THERAPEUTICS INC
Macrocyclic compounds for the treatment of proliferative diseases
The compounds and salts of the present invention inhibit kinases, especially the anaplastic lymphoma kinase (ALK) and the HGF receptor tyrosine kinase (RTK) c-Met, and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.
Owner:CS PHARMATECH LTD
Aptamer capable of binding to hgf receptor
ActiveUS20170275630A1Complicates quality controlCell culture mediaCell culture active agentsAptamerNucleotide
Provided is an aptamer including a polynucleotide of any of the following (a) to (c) and capable of binding to an HGF receptor to exhibit an activity of inhibiting the binding of HGF to the HGF receptor. (a) A polynucleotide consisting of a base sequence set forth in SEQ ID NO: 1, (b) A polynucleotide consisting of a base sequence having the deletion, substitution, insertion and / or addition of one to several bases in the base sequence set forth in SEQ ID NO: 1, and (c) A polynucleotide consisting of a base sequence having a sequence identity of 80% or more to the base sequence set forth in SEQ ID NO: 1.
Owner:THE UNIV OF TOKYO
Inhibitors of VEGF receptor and HGF receptor signaling
Owner:METHYLGENE
Quinoline compound and preparation method thereof, medicament combination containing compound and application of compound
The invention relates to a quinoline compound which is used as a c-Met depressant and is expressed by the general formula (I) below, a pharmaceutically acceptable salt or pharmaceutically acceptable solvate and a preparation method of the compound, a medicament combination containing the compound and application of the compounds in the preparation of medicaments for preventing or treating diseases relevant to abnormal cell proliferation, morphological change and hyperkinesia with respect to hepatocyte growth factor receptors (HGFR) in an organism as well as diseases relevant to angiogenesis or cancerometastasis, especially medicaments for treating or preventing growth and metastasis of tumors.
Owner:SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Trifluoro methyl substituted quinoline or quinoxaline compound and preparation method thereof, and pharmaceutical composition containing the compound and purpose thereof
The invention relates to a quinoline or quinoxaline compound shown as a following general formula I, pharmaceutically acceptable salt or pharmaceutically acceptable solvate thereof, and a preparation method thereof. The invention further relates to pharmaceutical composition containing the compound and / or pharmaceutically acceptable salt and / or pharmaceutically acceptable solvate thereof, and application of the pharmaceutical composition containing the compound and / or pharmaceutically acceptable salt and / or pharmaceutically acceptable solvate thereof to preparation of medicaments for preventing or treating diseases related to abnormal propagation, morphology and of cells and hyperkinesia that are related to hepatocyte growth factor receptor (HGFR) in organism, and diseases related to angiogenesis or cancerometastasis, and especially medicaments for preventing or treating tumour growth and cancerometastasis.
Owner:SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling
The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds of general formula (A)wherein A1 is sulfur, A3 is CH, A2 is CH, D is heterocycle, Z is oxygen, SO0-2 or NR, Ar is phenyl and G is not a ring, and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
Owner:MIRATI THERAPEUTICS INC
Substituted thieno[3,2-d]pyridines as inhibitors of the VEGF receptor and HGF receptor
![Substituted thieno[3,2-d]pyridines as inhibitors of the VEGF receptor and HGF receptor](https://images-eureka.patsnap.com/patent_img/af6a2e37-1283-469b-8105-c653838393af/US07772247-20100810-C00001.png "Substituted thieno[3,2-d]pyridines as inhibitors of the VEGF receptor and HGF receptor")
![Substituted thieno[3,2-d]pyridines as inhibitors of the VEGF receptor and HGF receptor](https://images-eureka.patsnap.com/patent_img/af6a2e37-1283-469b-8105-c653838393af/US07772247-20100810-C00002.png "Substituted thieno[3,2-d]pyridines as inhibitors of the VEGF receptor and HGF receptor")
![Substituted thieno[3,2-d]pyridines as inhibitors of the VEGF receptor and HGF receptor](https://images-eureka.patsnap.com/patent_img/af6a2e37-1283-469b-8105-c653838393af/US07772247-20100810-C00003.png "Substituted thieno[3,2-d]pyridines as inhibitors of the VEGF receptor and HGF receptor")
Owner:METHYLGENE
Antiviral Agent
An antiviral agent consisting of hepatocyte growth factor (HGF) or an agonist of the HGF receptor, and a medicament for prophylactic and / or therapeutic treatment of a disease caused by hepatitis C virus comprising using said agent simultaneously or separately with other anti-viral agent.
Owner:MITSUBISHI TANABE PHARMA CORP
Pharmaceutical composition containing hepatocyte growth factor receptor inhibitor and histone deacetylase inhibitor and application thereof
InactiveCN101653608AGood curative effectGood synergyAmide active ingredientsAntineoplastic agentsTreatment effectSide effect
The invention relates to a pharmaceutical composition containing a hepatocyte growth factor receptor (cMet) inhibitor and a histone deacetylase (HDAC) inhibitor, and application of the pharmaceutical composition in the preparation of medicaments for treating intestinal cancer, sarcoma, glioma, liver cancer, lung cancer, stomach cancer, brain tumors, pancreatic cancer, ovarian cancer, mammary cancer or prostate cancer. The pharmaceutical composition has significant synergistic effect, improves the treatment effect of the medicaments, reduces the administration dose and reduces side effects.
Owner:DINKUM INT INVESTMENT HONG KONG
Anti-c-met antibody showing enhanced stability or antigen-binding fragments thereof
ActiveCN113166244AImprove stabilityImprove productivityNervous disorderImmunoglobulins against cell receptors/antigens/surface-determinantsAntiendomysial antibodiesSide effect
Owner:HELIXMITH CO LTD
Anti-viral agent
InactiveCN101151046AOrganic active ingredientsPeptide/protein ingredientsAgonistTherapeutic treatment
An antiviral agent consisting of hepatocyte growth factor (HGF) or an agonist of the HGF receptor, and a medicament for prophylactic and / or therapeutic treatment of a disease caused by hepatitis C virus comprising using said agent simultaneously or separately with other anti-viral agent.
Owner:MITSUBISHI TANABE PHARMA CORP
Methods and compositions related to reduced met phosphorylation by leukocyte cell-derived chemotaxin 2 in tumor cells
It was discovered that leukocyte cell-derived chemotaxin 2 (LECT2) correlated with down-regulated vascular invasion in HCC patients. It was also found that LECT2 strongly reduced the growth, migration and invasiveness of HCC cells via inhibition of the phosphorylation of Met and other downstream targets in the HGF / MET pathway. The HXXXD motif of LECT2 was found to be important for its tumor inhibition mechanism. LECT2 reduced Met tyrosine phosphorylation and tumor cell invasion in other cancers, such as lung, breast, and gastric cancers, in addition to HCC. Methods and compositions for preventing, treating or diagnosing tumors, such as HCC, based on the newly discovered tumor suppression property of LECT2 are described.
Owner:TTY BIOPHARM
Inhibitors of protein tyrosine kinase activity
This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling and HGF receptor signaling. More particularly, the invention relates to compounds, compositions and methods for the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
Owner:MIRATI THERAPEUTICS INC
Method for inducing differentiation of pluripotent stem cells into hepatocytes
PendingCN111433353APromote maturityMicrobiological testing/measurementTransferasesPluripotential stem cellCultured cell
Provided is a method for preparing hepatocytes or cells that can be differentiated into hepatocytes from pluripotent stem cells for the purpose of preparing mature hepatocytes that are similar in manyrespects to primary cultured hepatocytes, wherein the method is characterized by including (1) a step for culturing pluripotent stem cells in a medium that contains an activator of activin receptor-like kinase-4,7, (2) a step for culturing the cells obtained in step (1) in a medium that contains an osteogenic factor and a fibroblast growth factor, (3) a step for culturing the cells obtained in step (2) in a medium that contains a hepatocyte growth factor receptor activator and an oncostatin M receptor activator, and (4) a step for culturing the cells obtained in step (3) and obtaining hepatocytes or cells that can be differentiated into hepatocytes, at least one of steps (2), (3), and (4) involving culturing the cells on a high-density collagen gel membrane.
Owner:TOKYO INST OF TECH +2
Novel pyridine derivative and pyrimidine derivative (3)
InactiveCN101198590BExcellent HGFR inhibitory effectOrganic active ingredientsOrganic chemistryAngiogenesis growth factorCancer metastasis
Owner:EISIA R&D MANAGEMENT CO LTD
Quinoline compound and preparation method thereof, medicament combination containing compound and application of compound
Owner:SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Inhibitors of VEGF receptor and hgf receptor signaling
The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds of general formula (A)wherein A1 is sulfur, A3 is CH, A2 is CH, D is heterocycle, Z is oxygen, SO0-2 or NR, Ar is phenyl and G is not a ring, and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
Owner:MIRATI THERAPEUTICS INC
Pharmaceutical composition containing hepatocyte growth factor receptor inhibitor and histone deacetylase inhibitor and application thereof
InactiveCN101653608BGood curative effectGood synergyAmide active ingredientsAntineoplastic agentsSide effectOncology
Owner:DINKUM INT INVESTMENT HONG KONG
Pyridine chemical, its preparation method, and pharmaceutical composition containing the chemical and application thereof
Owner:CHIA TAI TIANQING PHARMA GRP CO LTD
Method for producing intestinal cells from pluripotent stem cells
PendingCN112955541APromote maturityConnective tissue peptidesGastrointestinal cellsPluripotential stem cellEnterocyte differentiation
Provided is a method for producing intestinal cells derived from pluripotent stem cells, the produced intestinal cells exhibiting functions which are similar to those of actual intestinal cells. This method for producing intestinal cells uses a culture for differentiation into intestinal cells, which is characterized by containing a GSK3 inhibitor and one type selected from the group consisting of an activating agent for hepatocyte growth factor receptors, adrenal cortex hormone, calcitriol, and dimethyl sulfoxide.
Owner:TOKYO INST OF TECH +2
Trifluoro methyl substituted quinoline or quinoxaline compound and preparation method thereof, and pharmaceutical composition containing the compound and purpose thereof
The invention relates to a quinoline or quinoxaline compound shown as a following general formula I, pharmaceutically acceptable salt or pharmaceutically acceptable solvate thereof, and a preparation method thereof. The invention further relates to pharmaceutical composition containing the compound and / or pharmaceutically acceptable salt and / or pharmaceutically acceptable solvate thereof, and application of the pharmaceutical composition containing the compound and / or pharmaceutically acceptable salt and / or pharmaceutically acceptable solvate thereof to preparation of medicaments for preventing or treating diseases related to abnormal propagation, morphology and of cells and hyperkinesia that are related to hepatocyte growth factor receptor (HGFR) in organism, and diseases related to angiogenesis or cancerometastasis, and especially medicaments for preventing or treating tumour growth and cancerometastasis.
Owner:SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Inhibitors of protein tyrosine kinase activity
Owner:MIRATI THERAPEUTICS INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com